This is the first evidence showing increased LEAP2 serum levels in RA patients, which were correlated with inflammatory mediators, such as C-reactive protein (CRP), interleukin (IL)-6, IL-8, monocyte chemoattractant protein (MCP)-1, and lipocalin (LCN)-2. Here, IL6 is linked to rheumatoid arthritis.